PMID- 22007192
OWN - NLM
STAT- MEDLINE
DCOM- 20120202
LR  - 20211020
IS  - 1687-5303 (Electronic)
IS  - 1687-5214 (Print)
IS  - 1687-5214 (Linking)
VI  - 2012
DP  - 2012
TI  - Pharmacological inhibition of soluble epoxide hydrolase ameliorates diet-induced 
      metabolic syndrome in rats.
PG  - 758614
LID - 10.1155/2012/758614 [doi]
LID - 758614
AB  - The signs of metabolic syndrome following chronic excessive macronutrient intake 
      include body weight gain, excess visceral adipose deposition, hyperglycaemia, 
      glucose and insulin intolerances, hypertension, dyslipidaemia, endothelial 
      damage, cardiovascular hypertrophy, inflammation, ventricular contractile 
      dysfunction, fibrosis, and fatty liver disease. Recent studies show increased 
      activity of soluble epoxide hydrolase (sEH) during obesity and metabolic 
      dysfunction. We have tested whether sEH inhibition has therapeutic potential in a 
      rat model of diet-induced metabolic syndrome. In these high-carbohydrate, 
      high-fat-fed rats, chronic oral treatment with 
      trans-4-[4-(3-adamantan-1-ylureido)-cyclohexyloxy]-benzoic acid (t-AUCB), a 
      potent sEH inhibitor, alleviated the signs of metabolic syndrome in vivo 
      including glucose, insulin, and lipid abnormalities, changes in pancreatic 
      structure, increased systolic blood pressure, cardiovascular structural and 
      functional abnormalities, and structural and functional changes in the liver. The 
      present study describes the pharmacological responses to this selective sEH 
      inhibitor in rats with the signs of diet-induced metabolic syndrome.
FAU - Iyer, Abishek
AU  - Iyer A
AD  - School of Biomedical Sciences, The University of Queensland, Brisbane, QLD, 
      Australia.
FAU - Kauter, Kathleen
AU  - Kauter K
FAU - Alam, Md Ashraful
AU  - Alam MA
FAU - Hwang, Sung Hee
AU  - Hwang SH
FAU - Morisseau, Christophe
AU  - Morisseau C
FAU - Hammock, Bruce D
AU  - Hammock BD
FAU - Brown, Lindsay
AU  - Brown L
LA  - eng
GR  - R01 ES002710/ES/NIEHS NIH HHS/United States
GR  - R01 HL059699/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20111010
PL  - United States
TA  - Exp Diabetes Res
JT  - Experimental diabetes research
JID - 101274844
RN  - 0 (4-(4-(3-adamantan-1-ylureido)cyclohexyloxy)benzoic acid)
RN  - 0 (Benzoates)
RN  - 0 (Blood Glucose)
RN  - 0 (Dietary Carbohydrates)
RN  - 0 (Dietary Fats)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Lipids)
RN  - 8W8T17847W (Urea)
RN  - EC 3.3.2.- (Epoxide Hydrolases)
SB  - IM
MH  - Adipose Tissue/pathology
MH  - Animals
MH  - Benzoates/*therapeutic use
MH  - Blood Glucose/analysis
MH  - Cardiovascular System/pathology/physiopathology
MH  - *Diet
MH  - Dietary Carbohydrates/administration & dosage
MH  - Dietary Fats/administration & dosage
MH  - Enzyme Inhibitors/*therapeutic use
MH  - Epoxide Hydrolases/*antagonists & inhibitors
MH  - Lipids/blood
MH  - Liver/pathology
MH  - Male
MH  - Metabolic Syndrome/pathology/physiopathology/*prevention & control
MH  - Pancreas/pathology
MH  - Rats
MH  - Rats, Wistar
MH  - Urea/*analogs & derivatives/therapeutic use
PMC - PMC3191770
EDAT- 2011/10/19 06:00
MHDA- 2012/02/03 06:00
PMCR- 2011/10/10
CRDT- 2011/10/19 06:00
PHST- 2011/05/30 00:00 [received]
PHST- 2011/07/15 00:00 [revised]
PHST- 2011/07/15 00:00 [accepted]
PHST- 2011/10/19 06:00 [entrez]
PHST- 2011/10/19 06:00 [pubmed]
PHST- 2012/02/03 06:00 [medline]
PHST- 2011/10/10 00:00 [pmc-release]
AID - 10.1155/2012/758614 [doi]
PST - ppublish
SO  - Exp Diabetes Res. 2012;2012:758614. doi: 10.1155/2012/758614. Epub 2011 Oct 10.